Title:
Ｂ７−Ｈ１に対する標的結合剤
Document Type and Number:
Japanese Patent JP6480561
Kind Code:
B2
Abstract:
Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
Inventors:
Kebab, Christoph
Morrow, Michelle
Hammond, Scott
Alimzanov, Marat
Bab Cook, John
Forz, Ian
Gang, jaspar, sing
Sekirov, Laura
Boyle, Melanie
Shodorge, Matthew
Stewart, ross
Marglue, Kathleen Anne
Morrow, Michelle
Hammond, Scott
Alimzanov, Marat
Bab Cook, John
Forz, Ian
Gang, jaspar, sing
Sekirov, Laura
Boyle, Melanie
Shodorge, Matthew
Stewart, ross
Marglue, Kathleen Anne
Application Number:
JP2017250880A
Publication Date:
March 13, 2019
Filing Date:
December 27, 2017
Export Citation:
Assignee:
Medimun Limited
International Classes:
C07K16/28; A61K39/395; A61P35/00; C07K16/46
Domestic Patent References:
| JP2008544755A |
Foreign References:
| WO2004004771A1 | ||||
| WO2008083174A2 | ||||
| WO2008085562A2 |
Other References:
OKUDAIRA, K. et al.,"Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.",INT. J. ONCOL.,2009年10月,Vol.35, No.4,P.741-749
NOMI, T. et al.,"Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.",CLIN. CANCER RES.,2007年 4月 1日,Vol.13, No.7,P.2151-2157
NOMI, T. et al.,"Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.",CLIN. CANCER RES.,2007年 4月 1日,Vol.13, No.7,P.2151-2157
Attorney, Agent or Firm:
Yusuke Hiraki
Satoshi Fujita
Natsuo Tanaka
Satoshi Fujita
Natsuo Tanaka